{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ctDNA+testing&page=2",
    "query": {
      "intervention": "ctDNA testing",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ctDNA+testing&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T11:53:52.036Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02612350",
      "title": "Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mutation",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "ctDNA Analysis for the Detection of Genetic Mutations",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Pathway Genomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1106,
      "start_date": "2015-11",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02612350"
    },
    {
      "nct_id": "NCT07209215",
      "title": "ctDNA-Informed Management of Early-Stage Rectal Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma",
        "Rectal Cancer",
        "Early-stage Rectal Cancer",
        "Locally Advanced Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2026-10",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209215"
    },
    {
      "nct_id": "NCT05221827",
      "title": "Clinical Performance Evaluation of the C2i-Test",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "C2i Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "C2i Genomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "22 Years to 100 Years"
      },
      "enrollment_count": 3,
      "start_date": "2022-02-24",
      "completion_date": "2022-07-27",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "Bloomfield, New Jersey",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05221827"
    },
    {
      "nct_id": "NCT02948751",
      "title": "Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Leptomeningeal Metastasis"
      ],
      "interventions": [
        {
          "name": "OncoCEE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-02-06",
      "completion_date": "2019-12-18",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02948751"
    },
    {
      "nct_id": "NCT05174169",
      "title": "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stage III Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Signatera test",
          "type": "DEVICE"
        },
        {
          "name": "mFOLFOX6 3-6 month",
          "type": "DRUG"
        },
        {
          "name": "CAPOX 3 month",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6 6 month",
          "type": "DRUG"
        },
        {
          "name": "CAPOX 6 month",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1912,
      "start_date": "2022-07-08",
      "completion_date": "2030-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1037,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05174169"
    },
    {
      "nct_id": "NCT04068103",
      "title": "Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Stage IIA Colon Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 635,
      "start_date": "2019-12-16",
      "completion_date": "2026-06-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 932,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068103"
    },
    {
      "nct_id": "NCT04136002",
      "title": "Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Guardant Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "45 Years to 84 Years"
      },
      "enrollment_count": 44467,
      "start_date": "2019-10-08",
      "completion_date": "2027-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 271,
      "location_summary": "Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04136002"
    },
    {
      "nct_id": "NCT07069595",
      "title": "PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Residual Disease",
        "Triple Negative Breast Cancer (TNBC)",
        "Stage II/III"
      ],
      "interventions": [
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Circulating tumor DNA (ctDNA) testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2026-02-26",
      "completion_date": "2032-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07069595"
    },
    {
      "nct_id": "NCT07517705",
      "title": "MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Low-Dose Radiation Therapy (LDRT)",
          "type": "RADIATION"
        },
        {
          "name": "Standard Frontline Chemoimmunotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-06-12",
      "completion_date": "2032-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517705"
    },
    {
      "nct_id": "NCT02620527",
      "title": "Concordance Between ctDNA Assay and FoundationOne",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Circulating Tumor DNA",
        "Cancer",
        "Neoplasms",
        "Genomic Testing",
        "Genomic Alterations"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Foundation Medicine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1400,
      "start_date": "2014-11",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-06T11:53:52.036Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02620527"
    }
  ]
}